AKT1 and cancer: The findings of this study, specifically, the enrichment of PI3K-Akt, EGFR, MAPK, AMPK and ERK signalling in the NTRK1/2/3-high CRC subsets, are in consonance with the established signalling relationships of NTRK1/2/3 expression with cancer signalling pathways.